Xavron is a prescription drug product indicated for early empirical treatment of acute ischemic stroke or for the treatment of amyotrophic lateral sclerosis. According to the mechanism of action, Xavron is a blocker of the ischemic cascade.
The active substance of Xavron is edaravone, a compound created by Japanese scientists for the treatment of neurological diseases. Since 2009, edaravone has been included in the Japanese protocol for the treatment of acute ischemic stroke (grade B).
In acute ischemic stroke, Xavron is administered on prescription at a dose of 30 mg (1 ampoule) twice a day, morning and evening, by intravenous infusion for 30 minutes. Before administration, the contents of an ampoule should be dissolved in 100 ml of sodium chloride 0.9 %. Therapy should be initiated within 24 hours after the onset of symptoms.
The duration of treatment of acute ischemic stroke with Xavron is 14 days. In patients with acute ischemic stroke, the duration of therapy may be reduced depending on the clinical condition of the patient.
Contraindications to the administration of Xavron are: • Severe renal failure.
• Hypersensitivity to the components of the product.
Xavron is available in ampoules of 20 ml. Each ampoule contains 30 mg of edaravone. 2 or 10 ampoules per pack.